US antitrust cases continue to shape generic competition and pricing practices as policymakers seek to reduce drug costs

Generic competition and pricing practices continue to spearhead rise in US pharmaceutical antitrust cases

Arkansas bans PBMs from owning pharmacies, escalating scrutiny of vertical integration in pharmacy distribution

Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024

Where Things Stand on Drug Pricing at the Halfway Point of 2023

2022 Drug Pricing Update: States Continue Legislative Push Even As Congress Passes Long Sought Changes

Federal Legislators and FTC Keep PBMs Center Stage in Drug Pricing Debate

Drug Pricing Issues to Watch in 2022